Showing results (161-170 of 187) with videos related to

Sort By:
Pageof 19
Clinical Pharmacology and Therapeutics|October 4, 2006
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipientsMasahide Fukudo, Ikuko Yano, Satohiro Masuda, et al.
International Journal of Clinical Oncology|April 25, 2009
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patientsMasahide Onoue, Tomohiro Terada, Masahiko Kobayashi, et al.
Pharmaceutical Research|February 27, 2004
Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseasesYuji Sakurai, Hideyuki Motohashi, Harumasa Ueo, et al.
Pharmacogenetics and Genomics|December 18, 2009
Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patientsKana Toyama, Atsushi Yonezawa, Masahiro Tsuda, et al.
Therapeutic Drug Monitoring|May 15, 2014
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinomaTomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysisYosuke Togashi, Katsuhiro Masago, Masahide Fukudo, et al.
Basic & Clinical Pharmacology & Toxicology|April 1, 2008
Roles of organic anion transporters in the renal excretion of perfluorooctanoic acidHatsuki Nakagawa, Taku Hirata, Tomohiro Terada, et al.
Drug Metabolism and Pharmacokinetics|January 16, 2007
Temporal decline in sirolimus elimination immediately after pancreatic islet transplantationEriko Sato, Masahiro Shimomura, Satohiro Masuda, et al.
Pageof 19